A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood Acute Lymphoblastic Leukemia (ALL)

Cancer

Volumn 116, Issue 2, 2010, Pages 506-513

  Ladas, Elena J ^a   Kroll, David J ^b   Oberlies, Nicholas H ^c   Cheng, Bin ^d   Ndao, Deborah H ^a   Rheingold, Susan R ^e   Kelly, Kara M ^a  

^a NewYork Presbyterian Hospital   (United States)

^b NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^c RTI INTERNATIONAL   (United States)

^d Mailman School of Public Health ^*  (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Acute lymphoblastic leukemia; Childhood cancer; Complementary medicine; Hepatotoxicity; Milk thistle

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARAGINASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; MERCAPTOPURINE; METHOTREXATE; PLACEBO; SILYBUM MARIANUM EXTRACT; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; FLATULENCE; HEMATOLOGIC DISEASE; HUMAN; INFANT; INFECTION; IRRITABILITY; LIVER DISEASE; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; STOMACH PAIN;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; INFANT; LIVER FUNCTION TESTS; MALE; MILK THISTLE; PHYTOTHERAPY; PILOT PROJECTS; PLACEBOS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 75649125625     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24723     Document Type: Article

References (22)

1. Greenlee H, Abascal K, Yarnell E, et al. Clinical applications of Silybum marianum in oncology. Integr Cancer Ther. 2007;6:158-165.
2. Sagar SM. Future directions for research on Silybum marianum for cancer patients. Integr Cancer Ther. 2007;6:166-173.
3. Tamayo C, Diamond S. Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.). Integr Cancer Ther. 2007;6:146-157.
4. Comelli MC, Mengs U, Schneider C, et al. Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy. Integr Cancer Ther. 2007;6:120-129.
5. Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev. 2007;CD003620.
6. Invernizzi R, Bernuzzi S, Ciani D, et al. Silymarin during maintenance therapy of acute promyelocytic leukemia. Haematologica. 1993;78:340-341.
7. Schmiegelow K. Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1991;8:301-312.
8. Farrow AC, Buchanan GR, Zwiener RJ, et al. Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia. J Clin Oncol. 1997;15:1560-156.
9. Barzaghi N, Crema F, Gatti G, et al. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet. 1990;15:333-338.
10. Davis-Searles PR, Nakanishi Y, Kim NC, et al. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res. 2005;65:4448-4457.
11. Matloub Y, Lindemulder S, Gaynon PS, et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood. 2006;108:1165-1173.
12. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008; 111:2548-2555.
13. National Cancer Institute Common Toxicity Criteria. Bethesda, Maryland: National Cancer Institute; 2009.
14. Ladas EJ, Kroll D, Kelly K. Milk thistle. In: Coates P, Levine M, Blackman M, Moss J, Cragg G, White J. Encyclopedia of Dietary Supplements, 1st ed. New York, New York: Marcel Dekker; 2004:467-482.
15. Kim NC, Graf TN, Sparacino CM, et al. Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum). Org Biomol Chem. 2003;1:1684-1689.
16. Hoh C, Boocock D, Marczylo T, et al. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res. 2006;12:2944-2950.
17. Chou TC, Talaly P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci. 1983;4:450-454.
18. Straus SE, Chesney MA. Science and government. Enhanced: in defense of NCCAM. Science. 2006;313:303-304.
19. Parkman CA. The NCCAM and new research priorities. Case Manager. 2004;15:28-32.
20. Flaig TW, Gustafson DL, Su LJ, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs. 2007;25:139-146.
21. Malempati S, Gaynon PS, Sather H, La MK, Stork LC; Children's Oncology Group. Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952. J Clin Oncol. 2007;25:5800-5807.
22. Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004; 26:217-226.